Johnson & Johnson’s (NYSE: JNJ) sales in the third quarter were up 1.9% year-over-year with revenues of $23.8 billion and beating analysts’ estimates by $360 million.
Adjusted earnings came in at $2.55 per share, a decline of 1.9% year-over-year and surpassing analysts’ estimates of $2.48 per share.
Is JNJ a Buy or Sell?
Analysts are cautiously optimistic about JNJ with a Moderate Buy consensus rating based on six Buys and six Holds. The average price forecast for JNJ stock is $186.25 implies an upside potential of 11.8% at current levels.
